{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-055929","form_type":"8-K","ticker":"SCYX","cik":"0001178253","company_name":"SCYNEXIS INC","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.798844+00:00","generated_at":"2026-06-28T09:45:13.848089+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SCYNEXIS reports Q3 net loss $0.6M; BREXAFEMME net sales $0.5M in first partial quarter","bullets":["BREXAFEMME net sales $0.5M in partial Q3; IQVIA 1,006 prescriptions in Q3, 1,100 in October.","R&D expense $4.4M (-45% YoY); SG&A $15.4M (+341% YoY driven by commercial launch costs).","Net loss $0.6M ($0.02 per basic share) vs net income $0.9M in Q3 2020.","Cash $100.1M; runway projected into 2023.","CFO Eric Francois resigning; Danforth Advisors providing interim CFO Lawrence Hoffman."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-055929","json":"https://secwatch.observer/filing/0001564590-21-055929.json","markdown":"https://secwatch.observer/filing/0001564590-21-055929.md","text":"https://secwatch.observer/filing/0001564590-21-055929.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000156459021055929/0001564590-21-055929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000156459021055929/scyx-8k_20211110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:45:13.848089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}